Evidence map›Paper›PMID 40743359›Full record

ArticleScience (New York, N.Y.)2025

Evolving rare B cell lineages for an effective HIV vaccine.

Sallie R Permar, Patrick C Wilson

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Sallie R PermarDrukier Institute for Children's Health, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.
Patrick C WilsonDrukier Institute for Children's Health, Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Household Respiratory Virus SARS-CoV-2 Transmission and Immunity Sub-Study (HRTS)U01AI144616 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GORDON, AUBREE L, THOMAS, PAUL G. · 2019 to 2025
$43.7M
Project 2: The Isoform repertoire and epigenome of Pediatric SLEP50AR070594 · NIAMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Maria Virginia Pascual · 2016 to 2026
$18.6M
Project 2U19AI168632 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Octavio Ramilo · 2022 to 2026
$10.2M
A deep longitudinal analysis of next generation influenza vaccines in older adultsU01AI165452 · NIAID · JACKSON LABORATORY · PI Adolfo Garcia-Sastre, GEORGE A KUCHEL · 2022 to 2026
$9.0M
NIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS U01 AI144616NIAID NIH HHS U01 AI165452NIAID NIH HHS U19 AI168632NIAMS NIH HHS P50 AR070594
6 · The paper itself

Abstract

Clinical trials show that strategies to elicit the production of broadly neutralizing antibodies have a promising start.

Indexed as

AIDS VaccinesB-LymphocytesBroadly Neutralizing AntibodiesHIV-1HIV AntibodiesHIV InfectionsCell LineageClinical Trials as TopicHumansAIDS VaccinesBroadly Neutralizing AntibodiesHIV Antibodies

Identifiers

PMID40743359
PMCPMC12951596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.